474 related articles for article (PubMed ID: 27515827)
21. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
22. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
[TBL] [Abstract][Full Text] [Related]
23. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
24. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
25. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
[TBL] [Abstract][Full Text] [Related]
27. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
[TBL] [Abstract][Full Text] [Related]
28. MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Kim BR; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
PLoS One; 2016; 11(11):e0166096. PubMed ID: 27835666
[TBL] [Abstract][Full Text] [Related]
29. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
[TBL] [Abstract][Full Text] [Related]
31. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Clarke JL; Molinaro AM; Phillips JJ; Butowski NA; Chang SM; Perry A; Costello JF; DeSilva AA; Rabbitt JE; Prados MD
Neuro Oncol; 2014 Jul; 16(7):984-90. PubMed ID: 24637230
[TBL] [Abstract][Full Text] [Related]
32. Defining pseudoprogression in glioblastoma multiforme.
Van Mieghem E; Wozniak A; Geussens Y; Menten J; De Vleeschouwer S; Van Calenbergh F; Sciot R; Van Gool S; Bechter OE; Demaerel P; Wilms G; Clement PM
Eur J Neurol; 2013 Oct; 20(10):1335-41. PubMed ID: 23679051
[TBL] [Abstract][Full Text] [Related]
33. Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
Hagiwara A; Schlossman J; Shabani S; Raymond C; Tatekawa H; Abrey LE; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Cloughesy TF; Ellingson BM
J Neurooncol; 2022 Sep; 159(3):509-518. PubMed ID: 35842871
[TBL] [Abstract][Full Text] [Related]
34. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
35. Radiographic patterns of relapse in glioblastoma.
Chamberlain MC
J Neurooncol; 2011 Jan; 101(2):319-23. PubMed ID: 21052776
[TBL] [Abstract][Full Text] [Related]
36. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
37. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
[TBL] [Abstract][Full Text] [Related]
38. Lomustine and Bevacizumab in Progressive Glioblastoma.
Wick W; Gorlia T; Bendszus M; Taphoorn M; Sahm F; Harting I; Brandes AA; Taal W; Domont J; Idbaih A; Campone M; Clement PM; Stupp R; Fabbro M; Le Rhun E; Dubois F; Weller M; von Deimling A; Golfinopoulos V; Bromberg JC; Platten M; Klein M; van den Bent MJ
N Engl J Med; 2017 Nov; 377(20):1954-1963. PubMed ID: 29141164
[TBL] [Abstract][Full Text] [Related]
39. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Kebir S; Schaub C; Junold N; Hattingen E; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Galldiks N; Weller J; Mack F; Tzaridis T; Bähr O; Seidel C; Schlegel U; Schmidt-Graf F; Rohde V; Borchers C; Tabatabai G; Hänel M; Sabel M; Gerlach R; Krex D; Belka C; Vatter H; Proescholdt M; Glas M; Herrlinger U
J Neurooncol; 2019 Sep; 144(3):501-509. PubMed ID: 31325144
[TBL] [Abstract][Full Text] [Related]
40. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Kovic B; Xie F
J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
